Cargando…
A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systema...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466573/ https://www.ncbi.nlm.nih.gov/pubmed/30897759 http://dx.doi.org/10.3390/antibiotics8010030 |
_version_ | 1783411135146360832 |
---|---|
author | Lounsbury, Nicole Reeber, Mary G. Mina, Georges Chbib, Christiane |
author_facet | Lounsbury, Nicole Reeber, Mary G. Mina, Georges Chbib, Christiane |
author_sort | Lounsbury, Nicole |
collection | PubMed |
description | Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systematic overview was conducted by searching PubMed, Medline, and The Cochrane Library up to January 2019. Study selection and data extraction: All English-language clinical trials and case reports related to the efficacy of ceftaroline in new, not-yet-approved FDA indications in MRSA infections in pediatric or adult populations. Data synthesis: In the case of MRSA bacteremia (MRSAB) infections, three different randomized studies in pediatric patients showed effectiveness of ceftaroline. When used in the case of adult populations with MRSA bacteremia, a small trial of 16 patients showed 50% clinical success in patients with acute bacterial skin and skin structure infections versus 63% clinical success in patients with community-acquired bacterial pneumonia. Another case series of six refractory case reports showed 50% clinical success of ceftaroline in patients with MRSA. Conclusions: Although there are few case reports and limited data to date, ceftaroline fosamil should continue to be studied as an alternative therapy in MRSA infections in both pediatric and adult populations. Clinical success rates of ceftaroline were, in most cases, considered high when treating patients with MRSA infection. More clinical trials need to be studied. In the specific case of MRSA bacteremia, the treatment options remain few and ceftaroline should be extensively studied for the salvage treatment of MRSAB. |
format | Online Article Text |
id | pubmed-6466573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64665732019-04-18 A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Lounsbury, Nicole Reeber, Mary G. Mina, Georges Chbib, Christiane Antibiotics (Basel) Review Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations. Data sources: A systematic overview was conducted by searching PubMed, Medline, and The Cochrane Library up to January 2019. Study selection and data extraction: All English-language clinical trials and case reports related to the efficacy of ceftaroline in new, not-yet-approved FDA indications in MRSA infections in pediatric or adult populations. Data synthesis: In the case of MRSA bacteremia (MRSAB) infections, three different randomized studies in pediatric patients showed effectiveness of ceftaroline. When used in the case of adult populations with MRSA bacteremia, a small trial of 16 patients showed 50% clinical success in patients with acute bacterial skin and skin structure infections versus 63% clinical success in patients with community-acquired bacterial pneumonia. Another case series of six refractory case reports showed 50% clinical success of ceftaroline in patients with MRSA. Conclusions: Although there are few case reports and limited data to date, ceftaroline fosamil should continue to be studied as an alternative therapy in MRSA infections in both pediatric and adult populations. Clinical success rates of ceftaroline were, in most cases, considered high when treating patients with MRSA infection. More clinical trials need to be studied. In the specific case of MRSA bacteremia, the treatment options remain few and ceftaroline should be extensively studied for the salvage treatment of MRSAB. MDPI 2019-03-20 /pmc/articles/PMC6466573/ /pubmed/30897759 http://dx.doi.org/10.3390/antibiotics8010030 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lounsbury, Nicole Reeber, Mary G. Mina, Georges Chbib, Christiane A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections |
title | A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections |
title_full | A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections |
title_fullStr | A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections |
title_full_unstemmed | A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections |
title_short | A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections |
title_sort | mini-review on ceftaroline in bacteremia patients with methicillin-resistant staphylococcus aureus (mrsa) infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466573/ https://www.ncbi.nlm.nih.gov/pubmed/30897759 http://dx.doi.org/10.3390/antibiotics8010030 |
work_keys_str_mv | AT lounsburynicole aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT reebermaryg aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT minageorges aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT chbibchristiane aminireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT lounsburynicole minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT reebermaryg minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT minageorges minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections AT chbibchristiane minireviewonceftarolineinbacteremiapatientswithmethicillinresistantstaphylococcusaureusmrsainfections |